The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1496
ISSUE1496
June 6, 2016
Pimavanserin (Nuplazid) for Parkinson's Disease Psychosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Pimavanserin (Nuplazid) for Parkinson's Disease Psychosis
June 6, 2016 (Issue: 1496)
The FDA has approved the atypical antipsychotic
pimavanserin (Nuplazid – Acadia) for treatment
of hallucinations and delusions associated with
Parkinson's disease. It is the first drug to be approved
in the US for this indication.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.